Loading…
Loading…
AQSZF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AQSZF and 80,000+ other tickers.
See exactly how AQSZF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AQSZF and 80,000+ other tickers.
Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, dedicated to the development and commercialization of medicinal products across the country. The company concentrates its efforts on several key medical disciplines, including neurological conditions, ophthalmology, and transplantation medicine. Its current commercial portfolio features: Vistitan, an ophthalmic solution designed to lower elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Tacrolimus IR, an immunosuppressive drug prescribed for the…
VANCOUVER, British Columbia – TheNewswire - March 31, 2026 – Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“ Aequus ” or the “ Company ”), a specialty pharmaceutical company, today announced that it has completed the previously announced sale of its ZIMED® PF product to Luvo Medical Technologies Ltd. (“ Luvo ”) for aggregate consideration of approximately $531,693 (the “ Transaction ”). As the Transaction constituted the sale of all or substantially all of the assets of the Company pursuant to Section 301 of the Business Corporations Act (British Columbia), the Transaction was approved by the Company's shareholders at the Annual General and Special Meeting held on November 21, 2025 (the “ Meeting ”). For additional details regarding the Transaction, please refer to the Company's news release dated May 23, 2025 and the information circular dated October 20, 2025 related to the Meeting (the “ Information Circular ”). The Transaction was completed pursuant to the asset purchase agreement dated May 22, 2025 between Aequus and Luvo (the “ Purchase Agreement ”) as amended pursuant to an amending agreement dated March 30, 2026. The Purchase Agreement was amended to, among other things, replace the ongoing 6% royalty obligation originally contemplated thereby with a one-time lump sum royalty payment in an amount equal to approximately $131,693, thereby increasing the aggregate consideration payable to the Company from approximately $400,000 to $531,693. As there are no further ongoing royalty obligations, the Company will no longer be pursuing the assignment of the royalty to Douglas Janzen, the Chief Executive Officer of the Company, as described in the Information Circular.
VANCOUVER, November 13th, 2025 – TheNewswire - Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”) wishes to provide certain additional information in connection with the Company's upcoming annual general and special meeting of its shareholders (the “Meeting”), at the request of the Ontario Securities Commission. The Meeting is scheduled to be held on November 21, 2025. The Company wishes to provide the following additional disclosure to supplement the disclosure in the management information circular dated October 20, 2025 (the “Circular”) related to the Meeting. Except as described below, the Circular remains unchanged from the version that was mailed to shareholders of the Company and filed on SEDAR+.
VANCOUVER, November 12, 2025 – TheNewswire - Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”) wishes to provide certain additional information in connection with the Company's upcoming annual general and special meeting of its shareholders (the “Meeting”), at the request of the Ontario Securities Commission. The Meeting is scheduled to be held on November 21, 2025. The Company wishes to provide the following additional disclosure to supplement the disclosure in the management information circular dated October 20, 2025 (the “Circular”) related to the Meeting. Except as described below, the Circular remains unchanged from the version that was mailed to shareholders of the Company and filed on SEDAR+.
VANCOUVER, September 22 nd , 2025 – TheNewswire - Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, is pleased to announce Giovanni Di Genova has agreed to join the Aequus Board of Directors, subject to the completion of his PIF and TSX approval, effective Friday September 12 th , 2025. “Aequus is pleased to welcome Giovanni Di Genova as a new director and we are eager to work with him on
VANCOUVER – TheNewswire - May 21 st , 2025 – Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, today reports financial results for the quarter ended March 31st, 2025 (“First Quarter 2025”). Unless otherwise noted, all figures are in Canadian currency. Financial Report Highlights